On August 29, 2019 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, reported that management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York City on Monday, September 9, 2019 at 1:40 p.m. ET (Press release, Kaleido Biosciences, AUG 29, 2019, View Source [SID1234540068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available through the Investors & Media section of Kaleido’s website at View Source An archived replay will be accessible for 90 days following the event.

On August 29, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 2019 Wells Fargo Global Healthcare Conference on Wednesday, September 4, 2019 at 11:25 a.m. ET (Press release, MEI Pharma, AUG 29, 2019, View Source [SID1234539132]). The conference will take place September 4‐5, in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

On August 29, 2019 Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported that the Company will be presenting at the 4th annual Disruptive Growth Conference on Wednesday, September 4th at 3:40PM EST in Presentation Room A/B (Press release, Citius Pharmaceuticals, AUG 29, 2019, View Source [SID1234539133]). During the conference, Executive Chairman, Mr. Leonard Mazur will be giving the presentation as well as answering questions from investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the Company, please contact Mr. Andrew Scott: [email protected].

The 2018 Disruptive Growth Conference will offer the exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.

On August 29, 2019 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company’s two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the RHK Capital 2019 Disruptive Growth Conference on Wednesday, September 4, 2019 at 9:20 AM EDT (Press release, Soligenix, AUG 29, 2019, View Source [SID1234539134]). The event will take place at 599 Lexington Avenue, 22nd floor, New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the Soligenix corporate presentation, please visit here.

About 2019 Disruptive Growth Conference

The 2019 (4th Annual) Disruptive Growth Conference organized by RHK Capital, and hosted by Reed Smith, offers an exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.

For more information about the conference, please refer to the conference website.

On August 29, 2019 Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, reported that management plans to participate at the following events in September 2019 (Press release, Celyad, AUG 29, 2019, View Source [SID1234539118]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference
Date: Wednesday, September 4, 2019
Presentation Time: 4:10 p.m. EDT
Location: Boston, Massachusetts, USA
Webcast: Celyad’s website, under Events & Webcasts section

CAR-TCR Summit
Date: September 10 – 13, 2019
Location: Boston, Massachusetts, USA

International Conference on Lymphocyte Engineering (ICLE)
Date: September 13 – 15, 2019
Location: London, United Kingdom

KBC Annual Healthcare Conference
Date: Thursday, September 26, 2019
Location: Brussels, Belgium